Replies to post #327522 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Link to the slides of Dr. Liau's talk is at the bottom.

Here are some points of Dr. Liau's talk:

1. No financial interest in NWBO.

2. Patients don't want to be in the control arm.

3. Majority of patients enrolled after 2011.

4. Interpretation of progression changed over the years (slide 17).

5. Pseudo-progression is a problem with these trials.

6. Over time (after a max of 6 months), the progression goes away.

7. 5 years last month since the last patient enrollment.

8. Waiting for unblinded results.

9. How to push this to FDA for approval: good for patients.

10. Combination approaches (slide 30): do not increase the number of T-cells, but enhances activation.

11. Design trials - different control groups share drugs.

12. Conclusions (slide 31).

Slides of Dr. Liau's talk at UAB, November 6, 2020